Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib ...

Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Pembrolizumab, an anti–programmed death 1 (PD-1) monoclonal antibody, is a cornerstone of first-line standard care for recurrent and metastatic HNSCC. 1,2,7 The addition of pembrolizumab to ...

PURPOSEPembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and ...

Pembrolizumab is an anti–PD-1 monoclonal antibody that has shown promising efficacy and manageable safety as monotherapy in patients with cervical cancer. 1,2 The phase III KEYNOTE-826 study evaluated ...

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...